New pooled analysis published in The Lancet demonstrated reduced risk of combined CV death or worsening heart failure with semaglutide

Analysis conducted among 3,743 patients with history of heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction (HFpEF) from four clinical trials1 Obesity considered key driver in the development of HFpEF,2 with approximately 80% of people…